Overview Financials News + Filings Key Docs Transactions Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Tango Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/07/2023 |
8-K
| Quarterly results|
Docs:
|
"Consolidated Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Collaboration revenue 9,598 5,771 15,364 11,529 License revenue 5,000 — 5,000 — Total revenue 14,598 5,771 20,364 11,529 Operating expenses: Research and development 28,671 23,741 56,710 48,071 General and administrative 9,174 7,232 17,188 14,039 Total operating expenses 37,845 30,973 73,898 62,110 Loss from operations Other income, net 2,601 347 4,880 518 Provision for income taxes Net loss $ $ $ $ Net loss per common share – basic and diluted $ $ $ $ Weighted average number of common shares outstanding – basic and diluted 88,354,590 87,839,804 88,281,368 87,775,440 Condensed Consolidated Balance Sheets June 30, 2023 December 31, 2022 Assets Current assets: Cash and cash equ..." |
|
| 05/09/2023 |
8-K
| Quarterly results|
Docs:
|
"Consolidated Statements of Operations Three Months Ended March 31, 2023 2022 Total revenue 5,766 5,758 Operating expenses: Research and development 28,039 24,330 General and administrative 8,013 6,807 Total operating expenses 36,052 31,137 Loss from operations Other income, net 2,278 171 Net loss $ $ Net loss per common share – basic and diluted $ $ Weighted average number of common shares outstanding – basic and diluted 88,193,917 87,670,653 Condensed Consolidated Balance Sheets March 31, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 57,252 $ 59,968 Marketable securities 276,387 306,165 Accounts receivable — 2,000 Restricted cash — 567 Prepaid expenses and other current assets 9,361 6,572 Total current assets 343,000 375,272 Property and equipment, net 11,106 ..." |
|
| 03/27/2023 |
8-K
| Quarterly results|
Docs:
|
"Consolidated Statements of Operations Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Total revenue 6,411 5,716 24,860 37,042 Operating expenses: Research and development 29,091 21,634 105,906 77,636 General and administrative 7,887 6,066 30,025 17,596 Total operating expenses 36,978 27,700 135,931 95,232 Loss from operations Other income, net 1,558 115 2,949 247 Loss before income taxes Provision for income taxes Net loss $ $ $ $ Net loss per common share – basic and diluted $ $ $ $ Weighted average number of common shares outstanding – basic and diluted 87,971,485 87,567,676 87,820,037 62,108,032 Consolidated Balance Sheets December 31, 2022 2021 Assets Current assets: Cash and cash equivalents $ 59,968 $ 142,745 Marketable securities 306,165 342,510 Acc..." |
|
| 08/10/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
8-K
| Quarterly results |
| 03/28/2022 |
8-K
| Quarterly results |
| 11/09/2021 |
8-K
| Quarterly results |
|
|